Overview
- On July 15, Johnson & Johnson reported adjusted Q2 EPS of $2.90 and revenue of $25.31 billion, topping Wall Street estimates while the stock slipped about 2% in early trading.
- The pharmaceutical division led results with Innovative Medicine revenue of $16.38 billion driven by Darzalex at roughly $4.2 billion and Tremfya at about $2.0 billion.
- MedTech revenue was $8.93 billion, missing forecasts as Impella heart pump sales fell after a U.K. study raised questions about the device’s use in certain high‑risk procedures.
- Management raised full‑year guidance to about $101.1 billion in revenue and an $11.68 midpoint for adjusted EPS, signaling confidence in the company’s growth platforms.
- Analysts and investors will watch biosimilar-driven declines in Stelara, China’s procurement pressure, upcoming patent expirations and ongoing talc litigation as potential threats to J&J’s plan to reach roughly $100 billion in 2026 and higher long‑term growth.